BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)

Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether the respective boards breached fiduciary duties by failing to conduct fair processes and whether deal consideration provides fair value to shareholders.

06/22/2026, 1:47 PM • GlobeNewswire

Halper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their Shareholders

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

06/16/2026, 9:14 PM • GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG), Organon & Co. (NYSE – OGN)

Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Simulations Plus ($18.50/share), Roku ($160.00/share), TruBridge ($26.25/share), and Organon ($14.00/share).

06/16/2026, 3:56 PM • GlobeNewswire

Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders

Investor rights law firm Halper Sadeh LLC is investigating four major corporate transactions for potential securities law violations and breaches of fiduciary duties. The investigations cover Nuvalent's $124/share sale to GSK, SUNation Energy's merger with Suniva, Organon's $14/share sale to Sun Pharmaceutical, and Taylor Morrison's $72.50/share sale to Berkshire Hathaway. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

06/09/2026, 8:04 PM • GlobeNewswire

Hanmi Pharmaceutical se asocia con Organon para exportar terapias combinadas al Sudeste Asiático

Hanmi Pharmaceutical has signed a supply agreement with Organon to export three combination medicines in cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing, distribution, and sales in these markets, with potential for expansion in the medium to long term.

05/22/2026, 2:20 AM • GlobeNewswire

Hanmi Pharmaceutical Faz Parceria com a Organon para Exportação de Terapias de Combinação para o Sudeste Asiático

Hanmi Pharmaceutical has signed a supply agreement with Organon to export three combination medicines for cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing, distribution, and sales in these markets, with potential for medium to long-term expansion. The partnership leverages the growing demand for combination therapies in Southeast Asia's rapidly expanding pharmaceutical market.

05/22/2026, 2:20 AM • GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Veris Residential, Inc. (NYSE – VRE), XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX)

Brodsky & Smith law firm announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and pay fair value to shareholders. The investigations involve Veris Residential ($19.00/share), XOMA Royalty ($39.00/share), Organon ($14.00/share), and RE/MAX Holdings ($13.80/share or stock election).

05/14/2026, 1:51 PM • GlobeNewswire

Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

05/06/2026, 9:14 PM • GlobeNewswire

Halper Sadeh LLC is Investigating Whether MKC, LEG, OGN, KW are Obtaining Fair Deals for their Shareholders

Investor rights law firm Halper Sadeh LLC is investigating four major companies for potential securities law violations and breaches of fiduciary duties. The investigations concern McCormick & Company's merger with Unilever's Foods business, Leggett & Platt's sale to Somnigroup International, Organon & Co.'s sale to Sun Pharmaceutical, and Kennedy-Wilson Holdings' sale to a consortium led by its CEO. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

05/05/2026, 2:53 PM • GlobeNewswire

Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcy

Sirius XM is in preliminary discussions to acquire iHeartMedia in a potential merger of America's largest satellite radio provider and radio station owner. Other major deals include Eli Lilly acquiring AI startup Profluent for up to $2.25 billion, Sun Pharmaceutical acquiring Organon for $11.75 billion, and Uber purchasing Hong Kong-based FlyTaxi. Meanwhile, several companies filed for bankruptcy including Wren Kitchens, FreshRealm, and Smokey Bones BBQ.

05/01/2026, 2:35 PM • Benzinga

Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders

Investor rights law firm Halper Sadeh LLC is investigating four pharmaceutical and real estate companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

04/27/2026, 9:23 PM • GlobeNewswire

Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal

Organon & Co. shares surged 16.87% to $13.16 after Sun Pharmaceutical Industries agreed to acquire the women's health company in an all-cash deal valued at $14 per share. The acquisition, expected to close in early 2027, comes as relief for Organon, which has struggled since its 2021 spinoff from Merck with $8 billion in long-term debt and declining profitability.

04/27/2026, 5:34 PM • The Motley Fool

Stock Market Today: Dow Futures Fall, S&P 500 Gains As Trump Halts Iran Talks— Organon, SAP, Cheetah Net Supply Chain Service In Focus (UPDATED)

U.S. stock futures fell on Monday as President Trump canceled Iran talks, citing divisions within Tehran. The market awaits the Federal Reserve's Wednesday meeting with 100% likelihood of unchanged rates. Key movers include Organon jumping 15% on a $11.75B acquisition deal, SAP rising 6.14% on cloud adoption acceleration, and Cheetah Net plummeting 22.12% following a reverse stock split announcement.

04/27/2026, 8:33 AM • Benzinga

Sun Pharma Nears Final Offer For Organon In Largest Overseas Bet

Sun Pharmaceutical Industries is finalizing a $12 billion binding offer for Organon & Co., which would mark the largest overseas acquisition by an Indian pharmaceutical company. Sun Pharma has completed three months of due diligence and is arranging financing with multiple global banks before submitting a firm bid in the coming weeks. The acquisition aligns with Sun Pharma's strategy to become a more innovation-driven, branded pharmaceutical player.

04/10/2026, 10:57 AM • Benzinga

Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?

Sio Capital Management initiated a new $24.53 million position in Organon (OGN), purchasing 3.4 million shares at $6.03 per share. Despite the stock being down 61% over the past year, the investment signals potential turnaround opportunity as the pharmaceutical company focuses on stabilizing operations with flat 2026 guidance, supported by $1.9 billion in adjusted EBITDA despite declining revenues and profitability.

03/20/2026, 5:22 PM • The Motley Fool